查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584134

肺腺癌治療市場，按藥物類別、治療類型、治療階段、最終用戶、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Lung Adenocarcinoma Treatment Market, By Drug Class, By Therapy Type, By Stage of Treatment, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年肺腺癌治療市場規模為55,1209萬美元，2024年至2032年年複合成長率為10.70%。

肺腺癌治療市場-市場動態

吸菸率上升推動肺腺癌治療市場的成長

全球吸菸率不斷上升，大大促進了肺腺癌治療市場的成長，因為吸菸是肺癌的主要危險因子。世界衛生組織（WHO）估計，目前有超過 13億人吸煙，全球癌症相關死亡中近 22%是由菸草使用造成的。在美國，疾病管制與預防中心（CDC）報告指出，肺癌是癌症死亡的主要原因，其中約 85%的病例是由吸煙引起的。隨著公眾意識活動的加強和戒菸計畫的實施，對有效治療的需求預計將會增加。製藥公司透過投資創新療法（包括標靶治療和免疫療法）來應對這一趨勢，以應對不斷成長的患者群體。此外，美國肺臟協會等組織的措施目的是減少吸菸率並改善早期診斷，進一步推動肺腺癌領域對先進治療方案的需求。

肺腺癌治療市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 10.70%左右的年複合成長率成長

根據藥物類別細分，預計 EGFR 抑制劑將在2023年呈現最大市場佔有率

根據治療類型細分，2023年標靶治療為主導類型

根據治療階段細分，晚期或轉移性腺癌是2023年的主要類型

依地區分類，北美是2023年的主要收入來源

肺腺癌治療市場-細分分析：

全球肺腺癌治療市場根據藥物類別、治療類型、治療階段、最終用戶和地區進行細分。

根據藥物類別，市場分為四類：EGFR抑制劑、ALK抑制劑、PD-1/PD-L1抑制劑和VEGF抑制劑。 EGFR 抑制劑因其針對特定突變的有效性而具有最高優先順序。 ALK 抑制劑緊隨其後，為 ALK 陽性患者提供標靶治療，而 PD-1/PD-L1 抑制劑和 VEGF 抑制劑則提供了額外的治療選擇。

根據治療類型，市場分為四類：化療、標靶治療、免疫治療和合併治療。標靶治療因其在解決特定癌症突變方面的精確性而排名最高。接下來是免疫療法，利用免疫系統對抗癌症。聯合治療越來越受到關注，而化療仍然是標準但不太優先的選擇。

肺腺癌治療市場 - 地理洞察

北美是肺腺癌治療市場的領先地區，這主要是由於肺癌的高發病率和先進的醫療基礎設施。根據美國癌症協會預測，2023年，肺癌預計將占美國所有癌症死亡的25%左右。2022年，美國食品藥物管理局（FDA）批准了一種新的nivolumab和ipilimumab聯合療法治療晚期肺腺癌患者，突顯了治療方案的持續創新。歐洲緊隨其後，德國和英國等國家增加了對肺癌研究和個人化醫療方法的投資。歐洲腫瘤內科學會（ESMO）報告指出，在目的是早期檢測和預防的措施的支持下，越來越重視標靶治療。同時，由於吸菸率上升和醫療保健支出增加，亞太地區成為一個重要的市場，當地公司與全球製藥公司之間的合作促進了該地區獲得創新治療方法。

肺腺癌治療市場-競爭格局：

肺腺癌治療市場的競爭格局的特點是北美主要參與者的重大活動，由於先進的醫療基礎設施和肺癌的高盛行率，北美在市場佔有率方面處於領先地位。2023年，Roche、AstraZeneca等主要製藥公司宣布合作，加強標靶療法和免疫療法的開發。例如，AstraZeneca推出的新藥Tagrisso (osimertinib)在治療EGFR突變肺腺癌患者方面顯示出良好的前景，使其成為腫瘤學家的首選。此外，百時美施貴寶於2020年底收購了 MyoKardia，使他們能夠加強其腫瘤產品組合，並致力於肺癌治療。歐洲公司也在取得長足進步，諾華公司和歐洲癌症組織最近建立了合作夥伴關係，以改善患者獲得創新治療的機會。隨著競爭的加劇，進行中的臨床試驗和產品創新仍然非常重要，將塑造全球肺腺癌治療方案的未來格局。

最新進展：

2024年4月，FDA核准alectinib（Alecensa）作為腫瘤切除後間變性淋巴瘤激酶（ALK）陽性非小細胞肺癌（NSCLC）患者的輔助治療，且此病情經FDA核准的檢驗證實。

2024年3月，Pfizer Inc.公佈了3期CROWN試驗的長期追蹤結果，該試驗評估了LORBRENA（lorlatinib）的療效，一種第三代 ALK 抑制劑，針對未經治療的晚期變性淋巴瘤激酶 (ALK) 陽性非小細胞肺癌 (NSCLC) 患者，針對 XALKORI（crizotinib）。

目錄

第1章 肺腺癌治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依藥物類別分類的肺腺癌治療市場摘錄
    • 依治療類型分類的肺腺癌治療市場摘錄
    • 依治療階段分類的肺腺癌治療市場摘錄
    • 依最終使用者的肺腺癌治療市場摘錄
    • 依國家分類的肺腺癌治療市場摘錄
    • 依地區分類的肺腺癌治療市場摘錄
  • 競爭洞察

第3章 肺腺癌治療主要市場趨勢

  • 肺腺癌治療市場促進因素
    • 市場促進因素的影響分析
  • 肺腺癌治療市場限制
    • 市場限制影響分析
  • 肺腺癌治療市場機會
  • 肺腺癌治療市場未來趨勢

第4章 肺腺癌治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 肺腺癌治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 肺腺癌治療市場格局

  • 2023年肺腺癌治療市場佔有率分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 肺腺癌治療市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • EGFR抑制劑
    • ALK 抑制劑
    • PD-1/PD-L1 抑制劑
    • 血管內皮生長因子抑制劑

第8章 肺腺癌治療市場 - 依治療類型

  • 概述
    • 依治療類型分類的細分市場佔有率分析
    • 化療
    • 標靶治療
    • 免疫療法
    • 聯合療法

第9章 肺腺癌治療市場 - 依治療階段

  • 概述
    • 依治療階段分類的細分市場佔有率分析
    • 早期腺癌
    • 晚期或轉移性腺癌

第10章 肺腺癌治療市場 - 依最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 醫院
    • 腫瘤科診所
    • 研究機構

第11章 肺腺癌治療市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美肺腺癌治療主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依治療類型）
    • 北美市場規模與預測（依治療階段）
    • 北美市場規模和預測（依最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲肺腺癌治療主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模和預測（依治療類型）
    • 歐洲市場規模與預測（依治療階段）
    • 歐洲市場規模和預測（依最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區肺腺癌治療主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依治療類型）
    • 亞太地區市場規模與預測（依治療階段）
    • 亞太地區市場規模和預測（依最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲肺腺癌治療主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依治療類型）
    • 拉丁美洲市場規模與預測（依治療階段）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲肺腺癌治療主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模和預測（依治療類型）
    • 中東和非洲市場規模及預測（依治療階段）
    • 中東和非洲市場規模和預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他

第12章 主要供應商分析-肺腺癌治療產業

  • 競爭儀表板
  • 公司簡介
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Genentech, Inc.（Roche）
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Janssen Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Others

第13章 360 度分析師視角

第14章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4114

REPORT HIGHLIGHT

Lung Adenocarcinoma Treatment Market size was valued at USD 5,512.09 Million in 2023, expanding at a CAGR of 10.70% from 2024 to 2032.

The Lung Adenocarcinoma Treatment Market encompasses therapies specifically aimed at treating lung adenocarcinoma, a common subtype of non-small cell lung cancer. With rising global incidences, attributed to increased smoking rates and environmental factors, the market is witnessing significant growth. According to the American Cancer Society, approximately 236,000 new cases of lung cancer are expected in the U.S. in 2023, with adenocarcinoma accounting for nearly 40% of those cases. Advances in targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, are enhancing treatment options, while immunotherapy is gaining traction for its effectiveness in advanced stages. However, challenges such as high treatment costs and adverse side effects may hinder market expansion. Nevertheless, ongoing research and development initiatives aimed at improving existing therapies and the emergence of personalized medicine present substantial opportunities for market players, fostering innovations that could transform patient outcomes in lung adenocarcinoma treatment.

Lung Adenocarcinoma Treatment Market- Market Dynamics

Rising Smoking Rates Fuel Growth in the Lung Adenocarcinoma Treatment Market

The escalating rates of smoking worldwide significantly contribute to the growth of the Lung Adenocarcinoma Treatment Market, as smoking is a primary risk factor for lung cancer. The World Health Organization (WHO) estimates that over 1.3 billion people are currently smokers, with tobacco use accounting for nearly 22% of cancer-related deaths globally. In the United States, the Centers for Disease Control and Prevention (CDC) reports that lung cancer is the leading cause of cancer mortality, with smoking responsible for approximately 85% of cases. As public awareness campaigns increase and smoking cessation programs are implemented, the demand for effective treatments is anticipated to rise. Pharmaceutical companies are responding to this trend by investing in innovative therapies, including targeted treatments and immunotherapies, to address the growing patient population. Additionally, initiatives from organizations like the American Lung Association aim to reduce smoking prevalence and improve early diagnosis, further driving the need for advanced treatment options in the lung adenocarcinoma sector.

Lung Adenocarcinoma Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.70% over the forecast period (2024-2032)

Based on Drug Class segmentation, EGFR Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Stage of Treatment segmentation, Advanced or Metastatic Adenocarcinoma was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Lung Adenocarcinoma Treatment Market- Segmentation Analysis:

The Global Lung Adenocarcinoma Treatment Market is segmented on the basis of Drug Class, Therapy Type, Stage of Treatment, End-User, and Region.

The market is divided into four categories based on Drug Class: EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors, and VEGF Inhibitors. EGFR Inhibitors hold the highest priority due to their effectiveness in targeting specific mutations. ALK Inhibitors follow, offering targeted therapy for ALK-positive patients, while PD-1/PD-L1 Inhibitors and VEGF Inhibitors provide additional treatment options.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy ranks highest due to its precision in addressing specific cancer mutations. Immunotherapy follows, leveraging the immune system to combat cancer. Combination therapy is gaining traction, while chemotherapy remains a standard but less prioritized option.

Lung Adenocarcinoma Treatment Market- Geographical Insights

North America is a leading region in the Lung Adenocarcinoma Treatment Market, primarily due to high incidences of lung cancer and advanced healthcare infrastructure. According to the American Cancer Society, lung cancer is expected to account for about 25% of all cancer deaths in the U.S. in 2023. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy of nivolumab and ipilimumab for patients with advanced lung adenocarcinoma, highlighting the ongoing innovation in treatment options. Europe follows closely, with countries like Germany and the UK increasing investment in lung cancer research and personalized medicine approaches. The European Society for Medical Oncology (ESMO) reports a growing emphasis on targeted therapies, supported by initiatives aimed at early detection and prevention. Meanwhile, Asia-Pacific is emerging as a significant market due to rising smoking rates and increasing healthcare expenditure, with collaborations between local firms and global pharmaceutical companies facilitating access to innovative treatments across the region.

Lung Adenocarcinoma Treatment Market- Competitive Landscape:

The competitive landscape of the Lung Adenocarcinoma Treatment Market is characterized by significant activities from key players in North America, which leads in market share due to advanced healthcare infrastructure and a high prevalence of lung cancer. In 2023, major pharmaceutical companies such as Roche and AstraZeneca announced collaborations to enhance the development of targeted therapies and immunotherapies. For instance, AstraZeneca's launch of its new drug, Tagrisso (osimertinib), has shown promise in treating patients with EGFR-mutated lung adenocarcinoma, making it a preferred choice among oncologists. Additionally, Bristol-Myers Squibb's acquisition of MyoKardia in late 2020 has enabled them to bolster their oncology portfolio, focusing on lung cancer therapies. European companies are also making strides, with a recent partnership between Novartis and the European Cancer Organization to improve patient access to innovative treatments. As competition intensifies, ongoing clinical trials and product innovations remain critical, shaping the future landscape of lung adenocarcinoma treatment options globally.

Recent Developments:

In April 2024, the FDA approved alectinib (Alecensa) as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumor resection, with the condition confirmed by an FDA-approved test.

In March 2024, Pfizer Inc. announced the long-term follow-up results from the Phase 3 CROWN trial, which assessed the efficacy of LORBRENA (lorlatinib), a third-generation ALK inhibitor, against XALKORI (crizotinib) in patients with untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Genentech, Inc. (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • EGFR Inhibitors
  • ALK Inhibitors
  • PD-1/PD-L1 Inhibitors
  • VEGF Inhibitors

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY STAGE OF TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Early-Stage Adenocarcinoma
  • Advanced or Metastatic Adenocarcinoma

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology Clinics
  • Research Institutions

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Lung Adenocarcinoma Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Lung Adenocarcinoma Treatment Market Snippet by Drug Class
    • 2.1.2. Lung Adenocarcinoma Treatment Market Snippet by Therapy Type
    • 2.1.3. Lung Adenocarcinoma Treatment Market Snippet by Stage of Treatment
    • 2.1.4. Lung Adenocarcinoma Treatment Market Snippet by End-User
    • 2.1.5. Lung Adenocarcinoma Treatment Market Snippet by Country
    • 2.1.6. Lung Adenocarcinoma Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Lung Adenocarcinoma Treatment Key Market Trends

  • 3.1. Lung Adenocarcinoma Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Lung Adenocarcinoma Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Lung Adenocarcinoma Treatment Market Opportunities
  • 3.4. Lung Adenocarcinoma Treatment Market Future Trends

4. Lung Adenocarcinoma Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Lung Adenocarcinoma Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Lung Adenocarcinoma Treatment Market Landscape

  • 6.1. Lung Adenocarcinoma Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Lung Adenocarcinoma Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. EGFR Inhibitors
    • 7.1.3. ALK Inhibitors
    • 7.1.4. PD-1/PD-L1 Inhibitors
    • 7.1.5. VEGF Inhibitors

8. Lung Adenocarcinoma Treatment Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Immunotherapy
    • 8.1.5. Combination Therapy

9. Lung Adenocarcinoma Treatment Market - By Stage of Treatment

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Stage of Treatment, 2023 & 2032 (%)
    • 9.1.2. Early-Stage Adenocarcinoma
    • 9.1.3. Advanced or Metastatic Adenocarcinoma

10. Lung Adenocarcinoma Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Oncology Clinics
    • 10.1.4. Research Institutions

11. Lung Adenocarcinoma Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Lung Adenocarcinoma Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Lung Adenocarcinoma Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Lung Adenocarcinoma Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Lung Adenocarcinoma Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Lung Adenocarcinoma Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Lung Adenocarcinoma Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Astellas Pharma Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Boehringer Ingelheim GmbH
    • 12.2.6. Bristol-Myers Squibb Company
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Genentech, Inc. (Roche)
    • 12.2.9. Gilead Sciences, Inc.
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Janssen Pharmaceuticals, Inc.
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Takeda Pharmaceutical Company Limited
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us